Medipharm Labs (TSX: LABS) this morning announced changes to their leadership team within a brief news release that was issued. The company has revealed that current chief financial officer Robert (Bobby) Kwon has resigned from the company just barely a year after taking on the role.
Appointed to the position last November, Kwon effectively took over the role on November 18, 2019. At the time, he was hyped as being a highly experienced executive from the consumer packaged goods, retail and pharmaceutical industries with over twenty five years of experience.
Kwon is said to be leaving for family reasons, with his official departure taking place at the end of the month. An interim CFO is expected to fulfill the role until a permanent replacement can be found, with the search beginning immediately. Neither an interim or permanent replacement was named in this mornings announcement.
A further announcement with respect to the interim appointee is expected to be made at the end of the month.
Medipharm Labs last traded at $0.78 on the TSX.
.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.